Medications That Can Cause Depression
There is nothing more frustrating than when the cure is part of the problem. Because depression is prevalent in patients with physical disorders like cancer, stroke, and heart disease, medications often interact with each other, complicating treatment. To appropriately manage depression, you and your physician need to evaluate all medications involved and make sure they aren’t cancelling each other out.
A review in the journal Dialogues in Clinical Neuroscience a while back highlighted certain medications that can cause depression. The following are medications to watch out for.
Medications to Treat Seizures and Parkinso...
Source: World of Psychology - March 31, 2019 Category: Psychiatry & Psychology Authors: Therese J. Borchard Tags: Depression Medications Drug Interactions Mood Disorder Source Type: blogs
Last Month in Oncology with Dr. Bishal Gyawali
By BISHAL GYAWALI MD
Long list of news in lung cancer
September was an important month in oncology—especially for lung cancer. The World Conference in Lung Cancer (WCLC) 2018 gave us some important practice-changing results, also leading to four NEJM publications. The trial with most public health impact is unfortunately not published yet. It’s the NELSON trial that randomised more than 15000 asymptomatic people at high risk of lung cancer to either CT-based screening for lung cancer or to no screening and found a significant reduction in lung cancer mortality rates among the screened cohort compared with the contr...
Source: The Health Care Blog - January 4, 2019 Category: Consumer Health News Authors: matthew holt Tags: Research Bishal Gyawali Breast cancer Cancer drugs Clinical Trials health spending immunotherapy Lung cancer Oncology pembrolizumab Source Type: blogs
Yes, Providing Cancer Drugs In Multiple Vial Sizes Could Save Patients and Payers Money
On March 1, 2016, we published an article in the BMJ showing how in the US nearly $3 billion will be spent on discarded cancer drugs this year because companies package drugs in vials that contain too much of the drug for most doses, creating expensive leftover product. We proposed that companies in the US should either package drugs in more appropriate vial sizes to reduce the leftover amounts, or provide refunds for leftover drug.
Since the time of our article’s publication, numerous Senators have written letters to the Food and Drug Administration (FDA) urging action on vial sizes, and calling for the Department of He...
Source: Health Affairs Blog - June 8, 2016 Category: Health Management Authors: Peter Bach, Rena Conti, Raymond Muller, Geoffrey Schnorr and Leonard Saltz Tags: Costs and Spending Drugs and Medical Technology Cancer Source Type: blogs
Pharmalot... Pharmalittle... Good Morning
Hello, everyone, and nice to see you again. We have just emerged from a long summer weekend spent with our short people but, alas, the usual routine of meetings and deadlines has now returned. We hope your own battery is similarly recharged, but if not, please join us for that mandatory cup of stimulation as we dig in for another busy few days. As always, we have a menu of tidbits to help you get started. Hope your day goes well and do stay in touch...
Merck Halts Sale Of Feed Additive After Cattle Develop Problems (Bloomberg News)
Lilly Goes To Court To Defend Alimta Cancer Drug Administration Patent (Wall Street Journal)...
Source: Pharmalot - August 19, 2013 Category: Pharma Commentators Authors: esilverman Source Type: blogs
An interesting case
SAN DIEGO — A La Jolla oncologist was sentenced in San Diego federal court Tuesday to a year of probation, stemming from a scheme in which he and his practice treated patients with unapproved foreign cancer drugs, then fraudulently billed Medicare $1.7 million.Dr. Joel I. Bernstein’s sentence is in addition to the one his medical corporation received Friday. His practice was ordered to pay a $500,000 fine, forfeit $1.2 million and make restitution to Medicare for $1.7 million.The payments have all been paid, said his attorney, Charles Sevilla.A federal judge also sentenced the practice to a year of probation, mean...
Source: PharmaGossip - July 3, 2013 Category: Pharma Commentators Authors: insider Source Type: blogs
Lilly hit by Zyprexa losses | Pharmafile
Published on 30/01/13 at 11:33am The loss of exclusivity on Eli Lilly’s blockbuster antipsychotic Zyprexa hit the company hard in 2012, with the firm’s overall revenue falling 7% worldwide. The drug itself, licensed to treat schizophrenia and bipolar disorder, brought in as much as $5 billion in 2010, but had sales of just $1.7 billion last year - down 63% on 2011’s figure. Lilly’s turnover fell to $22.6 billion, although its pre-tax profit of $5.4 billion was up 1% year-on-year. Life without Zyprexa is proving as tough as Lilly predicted a year ago, and its troubles are far from over. Sales of an...
Source: PharmaGossip - January 30, 2013 Category: Pharma Commentators Authors: insider Source Type: blogs
Time to Refill Your Prescription For Zxygjfb
The brand names of drugs are famously odd. But they seem to be getting odder. That's the conclusion of a longtime reader, who sent this along:
I was recently perusing through the recent drug approval list and was struck by how strange the trade names have become. Perhaps it is a request from the FDA so that there are fewer prescription errors, but some of these are really bizarre and don't quite roll off the tongue. USAN names I can understand, but trade names, to me anyway, used to be much more polished (Viagra, Lipitor etc). Could it have to do with the fact that most of these are for cancer? I have a list below compar...
Source: In the Pipeline - January 28, 2013 Category: Chemists Tags: Business and Markets Source Type: blogs
